Gastrointestinal Cancer Therapy and Cardiotoxicity.

IF 3.8 2区医学 Q2 ONCOLOGY

Current Treatment Options in Oncology Pub Date : 2024-09-01 Epub Date: 2024-08-05 DOI:10.1007/s11864-024-01236-x

Orly Leiva, Talal El Zarif, Jose Alvarez-Cardona

引用次数: 0

Abstract

Opinion statement: Gastrointestinal cancers are a heterogenous group of cancers that share common risk factors with cardiovascular disease. Therapy for gastrointestinal cancers have improved cancer-specific outcomes at the cost of cardiotoxicity. The most common cardiotoxic therapies utilized in gastrointestinal cancers include conventional chemotherapy (including fluoropyrimidines and anthracyclines), targeted therapies including anti-vascular endothelial growth factor (VEGF) therapy and tyrosine kinase inhibitors (TKI), and immunotherapy. It is important for clinicians managing patients with gastrointestinal cancers to be aware of potential cardiotoxicity associated with these agents.

Abstract Image

查看原文本刊更多论文

胃肠道癌症治疗与心脏毒性

意见陈述：胃肠道癌症是一类异质性癌症，与心血管疾病有着共同的风险因素。胃肠道癌症的治疗以心脏毒性为代价，改善了癌症的特异性预后。胃肠道癌症最常见的心脏毒性疗法包括传统化疗（包括氟嘧啶类和蒽环类）、靶向疗法（包括抗血管内皮生长因子（VEGF）疗法和酪氨酸激酶抑制剂（TKI））以及免疫疗法。对于管理胃肠道癌症患者的临床医生来说，了解与这些药物相关的潜在心脏毒性非常重要。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current Treatment Options in Oncology ONCOLOGY-

CiteScore

7.10

自引率

0.00%

发文量

113

审稿时长

>12 weeks

期刊介绍： This journal aims to review the most important, recently published treatment option advances in the field of oncology. By providing clear, insightful, balanced contributions by international experts, the journal intends to facilitate worldwide approaches to cancer treatment. We accomplish this aim by appointing international authorities to serve as Section Editors in key subject areas, such as endocrine tumors, lymphomas, neuro-oncology, and cancers of the breast, head and neck, lung, skin, gastrointestinal tract, and genitourinary region. Section Editors, in turn, select topics for which leading experts contribute comprehensive review articles that emphasize new developments and recently published papers of major importance, highlighted by annotated reference lists. We also provide commentaries from well-known oncologists, and an international Editorial Board reviews the annual table of contents, suggests articles of special interest to their country/region, and ensures that topics are current and include emerging research.